Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met ...
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!
Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, ...
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years ...
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step ...
Changes in health care use emerged 5 to 6 years before the first clinical manifestation of MS, with shifts in encounter ...
At MSToronto 2026, investigators applied machine learning to health records, retinal scans, and blood samples to flag ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results